Other Events ·
Phathom Pharmaceuticals, Inc. announced the completion of patient enrollment for its Phase 2 pHalcon-EoE-201 clinical…
PHATPhathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. announced the completion of patient enrollment for its Phase 2 pHalcon-EoE-201 clinical trial, which evaluates VOQUEZNA (vonoprazan) for the treatment of eosinophilic esophagitis (EoE) in adults. The randomized, double-blind, placebo-controlled study has enrolled 95 patients across 41 U.S. sites, with topline results expected in the fourth quarter of 2026. Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing gastrointestinal treatments.